• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Dendritic cell-based immunotherapy in ovarian cancer.基于树突状细胞的卵巢癌免疫疗法。
Oncoimmunology. 2013 Dec 1;2(12):e27059. doi: 10.4161/onci.27059. Epub 2013 Nov 6.
2
Wilms' tumor gene 1 immunotherapy in pelvic gynecological malignancies.肾母细胞瘤基因1在盆腔妇科恶性肿瘤中的免疫治疗
Expert Rev Clin Immunol. 2014 Jun;10(6):705-11. doi: 10.1586/1744666X.2014.910119. Epub 2014 May 2.
3
Understanding dendritic cell immunotherapy in ovarian cancer.了解卵巢癌中的树突状细胞免疫疗法。
Expert Rev Anticancer Ther. 2016 Jun;16(6):643-52. doi: 10.1080/14737140.2016.1178576. Epub 2016 May 13.
4
Dendritic cell immunotherapy in ovarian cancer.树突状细胞免疫疗法在卵巢癌中的应用。
Expert Rev Anticancer Ther. 2013 Jan;13(1):43-53. doi: 10.1586/era.12.153.
5
Dendritic cell immunotherapy in uterine cancer.子宫癌中的树突状细胞免疫疗法。
Hum Vaccin Immunother. 2014;10(7):1822-7. doi: 10.4161/hv.28716.
6
Immunological response after WT1 mRNA-loaded dendritic cell immunotherapy in ovarian carcinoma and carcinosarcoma.WT1 mRNA 负载树突状细胞瘤苗免疫治疗卵巢癌及癌肉瘤的免疫反应
Anticancer Res. 2013 Sep;33(9):3855-9.
7
Dendritic cell-based immunotherapy targeting Wilms' tumor 1 in patients with recurrent malignant glioma.针对复发性恶性胶质瘤患者中威尔姆斯瘤1的基于树突状细胞的免疫疗法。
J Neurosurg. 2015 Oct;123(4):989-97. doi: 10.3171/2015.1.JNS141554. Epub 2015 Aug 7.
8
A Phase I/II trial comparing autologous dendritic cell vaccine pulsed either with personalized peptides (PEP-DC) or with tumor lysate (OC-DC) in patients with advanced high-grade ovarian serous carcinoma.一项Ⅰ/Ⅱ期临床试验，比较了自体树突状细胞疫苗（PEP-DC）或肿瘤裂解物（OC-DC）脉冲加载个体化肽在晚期高级别卵巢浆液性癌患者中的疗效。
J Transl Med. 2019 Nov 26;17(1):391. doi: 10.1186/s12967-019-02133-w.
9
Past, present and future strategies of immunotherapy in gynecological malignancies.妇科恶性肿瘤免疫治疗的过去、现在和未来策略。
Curr Mol Med. 2013 May;13(4):648-69. doi: 10.2174/1566524011313040014.
10
Dendritic Cells Loaded with Heat Shock-Conditioned Ovarian Epithelial Carcinoma Cell Lysates Elicit T Cell-Dependent Antitumor Immune Responses .负载热休克条件化卵巢上皮癌细胞裂解物的树突状细胞可诱导 T 细胞依赖的抗肿瘤免疫应答。
J Immunol Res. 2019 Nov 25;2019:9631515. doi: 10.1155/2019/9631515. eCollection 2019.

引用本文的文献

1
Identification and validation of differentially expressed proteins in epithelial ovarian cancers using quantitative proteomics.使用定量蛋白质组学鉴定和验证上皮性卵巢癌中差异表达的蛋白质
Oncotarget. 2016 Dec 13;7(50):83187-83199. doi: 10.18632/oncotarget.13077.
2
Trial watch: Naked and vectored DNA-based anticancer vaccines.试验观察：裸 DNA 与载体 DNA 抗癌疫苗。
Oncoimmunology. 2015 Apr 2;4(5):e1026531. doi: 10.1080/2162402X.2015.1026531. eCollection 2015 May.
3
Mulberry leaf polysaccharides modulate murine bone-marrow-derived dendritic cell maturation.桑叶多糖调节小鼠骨髓来源的树突状细胞成熟。
Hum Vaccin Immunother. 2015;11(4):946-50. doi: 10.1080/21645515.2015.1011977.
4
Study on the mesothelin-specific cytotoxicity against epithelial ovarian cancer with full-length mesothelin cDNA-transduced dendritic cells.全长间皮素cDNA转导的树突状细胞对上皮性卵巢癌的间皮素特异性细胞毒性研究。
Med Oncol. 2015 Apr;32(4):116. doi: 10.1007/s12032-015-0561-7. Epub 2015 Mar 17.
5
Classification of current anticancer immunotherapies.当前抗癌免疫疗法的分类。
Oncotarget. 2014 Dec 30;5(24):12472-508. doi: 10.18632/oncotarget.2998.

本文引用的文献

1
Immunological response after WT1 mRNA-loaded dendritic cell immunotherapy in ovarian carcinoma and carcinosarcoma.WT1 mRNA 负载树突状细胞瘤苗免疫治疗卵巢癌及癌肉瘤的免疫反应
Anticancer Res. 2013 Sep;33(9):3855-9.
2
Bevacizumab in the treatment of ovarian cancer.贝伐珠单抗治疗卵巢癌。
Adv Ther. 2012 Sep;29(9):723-35. doi: 10.1007/s12325-012-0041-9. Epub 2012 Aug 21.
3
Integration of autologous dendritic cell-based immunotherapy in the standard of care treatment for patients with newly diagnosed glioblastoma: results of the HGG-2006 phase I/II trial.自体树突状细胞瘤内免疫疗法与新诊断胶质母细胞瘤标准治疗的整合：HGG-2006 期 I/II 试验结果。
Cancer Immunol Immunother. 2012 Nov;61(11):2033-44. doi: 10.1007/s00262-012-1261-1. Epub 2012 Apr 22.
4
The secret ally: immunostimulation by anticancer drugs.抗癌药物的免疫刺激：秘密盟友
Nat Rev Drug Discov. 2012 Feb 3;11(3):215-33. doi: 10.1038/nrd3626.
5
Immunological response after therapeutic vaccination with WT1 mRNA-loaded dendritic cells in end-stage endometrial carcinoma.晚期子宫内膜癌患者经 WT1 信使核糖核酸负载树突状细胞瘤内免疫治疗后的免疫反应
Anticancer Res. 2010 Sep;30(9):3709-14.
6
Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer.新辅助化疗与初始肿瘤细胞减灭术用于 IIIC 或 IV 期卵巢癌。
N Engl J Med. 2010 Sep 2;363(10):943-53. doi: 10.1056/NEJMoa0908806.
7
Lumenal part of the DC-LAMP protein is not required for induction of antigen-specific T cell responses by means of antigen-DC-LAMP messenger RNA-electroporated dendritic cells.腔内部分的 DC-LAMP 蛋白对于通过抗原-DC-LAMP 信使 RNA 电穿孔树突状细胞诱导抗原特异性 T 细胞反应不是必需的。
Hum Gene Ther. 2010 Apr;21(4):479-85. doi: 10.1089/hum.2009.080.
8
The prioritization of cancer antigens: a national cancer institute pilot project for the acceleration of translational research.癌症抗原的优先级排序：美国国立癌症研究所加速转化研究的试点项目
Clin Cancer Res. 2009 Sep 1;15(17):5323-37. doi: 10.1158/1078-0432.CCR-09-0737.
9
DC-based cancer vaccines.基于树突状细胞的癌症疫苗。
J Clin Invest. 2007 May;117(5):1195-203. doi: 10.1172/JCI31205.
10
Electroporation of immature and mature dendritic cells: implications for dendritic cell-based vaccines.未成熟和成熟树突状细胞的电穿孔：对基于树突状细胞的疫苗的影响。
Gene Ther. 2005 May;12(9):772-82. doi: 10.1038/sj.gt.3302471.

基于树突状细胞的卵巢癌免疫疗法。

Dendritic cell-based immunotherapy in ovarian cancer.

作者信息

Coosemans An, Vergote Ignace, Van Gool Stefaan W

机构信息

Department of Gynecologic Oncology; Leuven Cancer Institute, KU Leuven, Belgium.

Department of Microbiology and Immunology; KU Leuven, Belgium.

出版信息

Oncoimmunology. 2013 Dec 1;2(12):e27059. doi: 10.4161/onci.27059. Epub 2013 Nov 6.

DOI:10.4161/onci.27059
PMID:24501688
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3913669/
Abstract

Worldwide, 80% of patients with ovarian cancer die of the disease. New treatments for this aggressive disease are therefore being intensively searched. Although dendritic cell-based vaccines against gynecological malignancies are in their infancy, this immunotherapeutic approach holds much promise. Here, we present our view on an optimal dendritic cell-based immunotherapeutic strategy against ovarian cancer.

摘要

在全球范围内，80%的卵巢癌患者死于该疾病。因此，人们正在积极寻找针对这种侵袭性疾病的新疗法。尽管基于树突状细胞的妇科恶性肿瘤疫苗尚处于起步阶段，但这种免疫治疗方法前景广阔。在此，我们阐述了针对卵巢癌的基于树突状细胞的最佳免疫治疗策略的观点。